Market capitalization | $293.16m |
Enterprise Value | $25.70m |
P/E (TTM) P/E ratio | 26.13 |
EV/FCF (TTM) EV/FCF | 0.40 |
EV/Sales (TTM) EV/Sales | 0.11 |
P/S ratio (TTM) P/S ratio | 1.31 |
P/B ratio (TTM) P/B ratio | 0.69 |
Revenue growth (TTM) Revenue growth | -50.46% |
Revenue (TTM) Revenue | $224.26m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
5 Analysts have issued a OraSure Technologies, Inc. forecast:
5 Analysts have issued a OraSure Technologies, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 224 224 |
50%
50%
|
|
Gross Profit | 103 103 |
45%
45%
|
|
EBITDA | 11 11 |
85%
85%
|
EBIT (Operating Income) EBIT | -1.29 -1.29 |
103%
103%
|
Net Profit | 11 11 |
77%
77%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.
Head office | United States |
CEO | Carrie Manner |
Employees | 638 |
Founded | 2000 |
Website | www.orasure.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.